TY - JOUR
T1 - Optogenetic modulation of intraocular pressure in a glucocorticoid-induced ocular hypertension mouse model
AU - Kowal, Tia J.
AU - Prosseda, Philipp P.
AU - Ning, Ke
AU - Wang, Biao
AU - Alvarado, Jorge
AU - Sendayen, Brent E.
AU - Jabbehdari, Sayena
AU - Stamer, W. Daniel
AU - Hu, Yang
AU - Sun, Yang
N1 - Funding Information:
Supported by NIH/NEI R01-EY032159 (Y.S.), R01-EY025295 (Y.S.), VA merit CX001298 (Y.S.), Children’s Health Research Institute Award (Y.S.). R01-EY-023295 (Y.H.), R01-EY024932 (Y.H.), EY028106 (Y.H.), EY031063 (Y.H.), and grants from Glaucoma Research Foundation (CFC3) (Y.H.), BrightFocus Foundation (Y.H.), and Chan Zuckerberg Initiative Neurodegeneration Collaborative Pairs Pilot Projects (Y.H.). Research for Prevention of Blind- ness Unrestricted grant (Stanford Ophthalmology) P30 Vision Center grant to Stanford Ophthalmology department. Y.S. is a Laurie Kraus Lacob Faculty Scholar in Pediatric Translational Medicine. This work was also supported by NIH/NEI T32 training grant T32-EY027816 and F32-EY032775-01 Kirschstein-NRSA postdoctoral fellowship (T.K.).
Funding Information:
Supported by NIH/NEI R01-EY032159 (Y.S.), R01-EY025295 (Y.S.), VA merit CX001298 (Y.S.), Children?s Health Research Institute Award (Y.S.). R01-EY-023295 (Y.H.), R01-EY024932 (Y.H.), EY028106 (Y.H.), EY031063 (Y.H.), and grants from Glaucoma Research Foundation (CFC3) (Y.H.), Bright Focus Foundation (Y.H.), and Chan Zuckerberg Initiative Neurodegeneration Collaborative Pairs Pilot Projects (Y.H.). Research for Prevention of Blindness Unrestricted grant (Stanford Ophthalmology) P30 Vision Center grant to Stanford Ophthalmology department. YS. is a Laurie Kraus Lacob Faculty Scholar in Pediatric Translational Medicine. This work was also supported by NIH/NEI T32 training grant T32-EY027816 and F32-EY032775-01 Kirschstein-NRSA postdoctoral fellowship (T.K.).
Publisher Copyright:
© 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - Purpose: Steroid-induced glaucoma is a common form of secondary open angle glaucoma characterized by ocular hypertension (elevated intraocular pressure [IOP]) in response to prolonged glucocorticoid exposure. Elevated IOP occurs with increased outflowwresistance and altered trabecular meshwork (TM) function. Recently, we used an optogenetic approach in TM to regulate the 5-phosphatase, OCRL, which contributes to regulating PI(4,5)P2 levels. Here, we applied this system with the aim of reversing compromised outflow function in a steroid-induced ocular hypertension mouse model. Methods: Elevated IOP was induced by chronic subconjunctival dexamethasone injections in wild-type C57Bl/6j mice. AAV2 viruses containing optogenetic modules of cryptochrome 2 (Cry2)-OCRL-5ptase and CIBN-GFP were injected into the anterior chamber. Four weeks after viral expression and dexamethasone exposure, IOP was measured by tonometer and outflow facility was measured by perfusion apparatus. Human TM cells were treatedwith dexamethasone, stimulated by light and treated with rhodamine-phalloidin to analyze actin structure. Results: Dexamethasone treatment elevated IOP and decreased outflow facility in wildtype mice. Optogenetic constructs were expressed in the TM of mouse eyes. Light stimulation caused CRY2-OCRL-5ptase to translocate to plasma membrane (CIBN-CAAX-GFP) and cilia (CIBN-SSTR3-GFP) in TM cells, which rescued the IOP and outflow facility. In addition, aberrant actin structures formed by dexamethasone treatment were reduced by optogenetic stimulation in human TM cells in culture. Conclusions: Subcellular targeting of inositol phosphatases to remove PIP2 represents a promising strategy to reverse defective TM function in steroid-induced ocular hypertension. Translational Relevance: Targeted modulation of OCRL may be used to decrease steroid-induced elevated IOP.
AB - Purpose: Steroid-induced glaucoma is a common form of secondary open angle glaucoma characterized by ocular hypertension (elevated intraocular pressure [IOP]) in response to prolonged glucocorticoid exposure. Elevated IOP occurs with increased outflowwresistance and altered trabecular meshwork (TM) function. Recently, we used an optogenetic approach in TM to regulate the 5-phosphatase, OCRL, which contributes to regulating PI(4,5)P2 levels. Here, we applied this system with the aim of reversing compromised outflow function in a steroid-induced ocular hypertension mouse model. Methods: Elevated IOP was induced by chronic subconjunctival dexamethasone injections in wild-type C57Bl/6j mice. AAV2 viruses containing optogenetic modules of cryptochrome 2 (Cry2)-OCRL-5ptase and CIBN-GFP were injected into the anterior chamber. Four weeks after viral expression and dexamethasone exposure, IOP was measured by tonometer and outflow facility was measured by perfusion apparatus. Human TM cells were treatedwith dexamethasone, stimulated by light and treated with rhodamine-phalloidin to analyze actin structure. Results: Dexamethasone treatment elevated IOP and decreased outflow facility in wildtype mice. Optogenetic constructs were expressed in the TM of mouse eyes. Light stimulation caused CRY2-OCRL-5ptase to translocate to plasma membrane (CIBN-CAAX-GFP) and cilia (CIBN-SSTR3-GFP) in TM cells, which rescued the IOP and outflow facility. In addition, aberrant actin structures formed by dexamethasone treatment were reduced by optogenetic stimulation in human TM cells in culture. Conclusions: Subcellular targeting of inositol phosphatases to remove PIP2 represents a promising strategy to reverse defective TM function in steroid-induced ocular hypertension. Translational Relevance: Targeted modulation of OCRL may be used to decrease steroid-induced elevated IOP.
KW - Dexamethasone
KW - Inositol phosphatase
KW - Intraocular pressure
KW - Primary cilia
KW - Steroid-induced glaucoma
UR - http://www.scopus.com/inward/record.url?scp=85106611275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106611275&partnerID=8YFLogxK
U2 - 10.1167/tvst.10.6.10
DO - 10.1167/tvst.10.6.10
M3 - Article
AN - SCOPUS:85106611275
VL - 10
JO - Translational Vision Science and Technology
JF - Translational Vision Science and Technology
SN - 2164-2591
IS - 6
M1 - 10
ER -